CA2281799A1 - Procedes et compositions servant a proteger les mitochondries - Google Patents
Procedes et compositions servant a proteger les mitochondries Download PDFInfo
- Publication number
- CA2281799A1 CA2281799A1 CA002281799A CA2281799A CA2281799A1 CA 2281799 A1 CA2281799 A1 CA 2281799A1 CA 002281799 A CA002281799 A CA 002281799A CA 2281799 A CA2281799 A CA 2281799A CA 2281799 A1 CA2281799 A1 CA 2281799A1
- Authority
- CA
- Canada
- Prior art keywords
- radiation
- ergothioneine
- damage
- mitochondria
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000003470 mitochondria Anatomy 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims abstract description 51
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 claims abstract description 102
- 230000005855 radiation Effects 0.000 claims abstract description 36
- 239000003642 reactive oxygen metabolite Substances 0.000 claims abstract description 35
- 239000002502 liposome Substances 0.000 claims abstract description 32
- 241000124008 Mammalia Species 0.000 claims abstract description 25
- 230000004792 oxidative damage Effects 0.000 claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 14
- 239000003937 drug carrier Substances 0.000 claims abstract description 11
- 230000000699 topical effect Effects 0.000 claims abstract description 7
- 238000001959 radiotherapy Methods 0.000 claims abstract description 5
- 230000036542 oxidative stress Effects 0.000 claims abstract description 3
- 238000007911 parenteral administration Methods 0.000 claims abstract description 3
- 230000006378 damage Effects 0.000 claims description 45
- 230000001413 cellular effect Effects 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 11
- 230000000254 damaging effect Effects 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- 230000006676 mitochondrial damage Effects 0.000 claims description 8
- 238000002485 combustion reaction Methods 0.000 claims description 7
- 208000002177 Cataract Diseases 0.000 claims description 6
- 241000208125 Nicotiana Species 0.000 claims description 6
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 6
- 230000002685 pulmonary effect Effects 0.000 claims description 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 5
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 5
- 239000005642 Oleic acid Substances 0.000 claims description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 5
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 5
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 4
- 206010057430 Retinal injury Diseases 0.000 claims description 4
- 230000001093 anti-cancer Effects 0.000 claims description 4
- 230000003412 degenerative effect Effects 0.000 claims description 4
- 230000005670 electromagnetic radiation Effects 0.000 claims description 4
- 239000003344 environmental pollutant Substances 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 231100000719 pollutant Toxicity 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010014561 Emphysema Diseases 0.000 claims description 3
- 208000018565 Hemochromatosis Diseases 0.000 claims description 3
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000019155 Radiation injury Diseases 0.000 claims description 3
- 208000031306 Rare hereditary hemochromatosis Diseases 0.000 claims description 3
- 208000014604 Specific Language disease Diseases 0.000 claims description 3
- 208000002903 Thalassemia Diseases 0.000 claims description 3
- 201000007201 aphasia Diseases 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 229910001385 heavy metal Inorganic materials 0.000 claims description 3
- 239000000017 hydrogel Substances 0.000 claims description 3
- 231100000268 induced nephrotoxicity Toxicity 0.000 claims description 3
- 238000007917 intracranial administration Methods 0.000 claims description 3
- 238000007913 intrathecal administration Methods 0.000 claims description 3
- 238000007914 intraventricular administration Methods 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 201000006938 muscular dystrophy Diseases 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 2
- -1 fallout Substances 0.000 claims description 2
- 239000003527 fibrinolytic agent Substances 0.000 claims description 2
- 230000003480 fibrinolytic effect Effects 0.000 claims description 2
- 239000003317 industrial substance Substances 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 231100000572 poisoning Toxicity 0.000 claims description 2
- 230000000607 poisoning effect Effects 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 108700012359 toxins Proteins 0.000 claims description 2
- 208000033116 Asbestos intoxication Diseases 0.000 claims 1
- 208000005374 Poisoning Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 206010003441 asbestosis Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 239000002699 waste material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- 230000001590 oxidative effect Effects 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 6
- 238000002405 diagnostic procedure Methods 0.000 abstract description 4
- 238000005538 encapsulation Methods 0.000 abstract description 4
- 239000007800 oxidant agent Substances 0.000 abstract description 4
- 235000005911 diet Nutrition 0.000 abstract description 3
- 206010073303 Exposure via inhalation Diseases 0.000 abstract description 2
- 230000000378 dietary effect Effects 0.000 abstract description 2
- 231100000317 environmental toxin Toxicity 0.000 abstract description 2
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 206010073306 Exposure to radiation Diseases 0.000 abstract 1
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 16
- 238000009472 formulation Methods 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 210000002510 keratinocyte Anatomy 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 7
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical group N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 7
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 238000000134 MTT assay Methods 0.000 description 4
- 231100000002 MTT assay Toxicity 0.000 description 4
- 230000008499 blood brain barrier function Effects 0.000 description 4
- 210000001218 blood-brain barrier Anatomy 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000002438 mitochondrial effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 238000012387 aerosolization Methods 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 229940034982 antineoplastic agent Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108010006654 Bleomycin Proteins 0.000 description 2
- 206010048610 Cardiotoxicity Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000010425 asbestos Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 231100000259 cardiotoxicity Toxicity 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 231100000760 phototoxic Toxicity 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 229910052895 riebeckite Inorganic materials 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 231100001243 air pollutant Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 231100000223 dermal penetration Toxicity 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000003700 hair damage Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000009092 tissue dysfunction Effects 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La protection des mitochondries contre une dégénérescence oxydative provoquée par des processus naturels ou pathologiques, ainsi que par les effets de facteurs exogènes, tels que les rayons solaires incidents, l'exposition par inhalation à des toxines oxydatives de l'environnement, la consommation d'oxydants alimentaires et les produits pharmaceutiques favorisant le stress oxydatif ou l'exposition à un rayonnement, y compris une radiothérapie, entre autres, est effectuée par une composition contenant L-ergothionéine. On peut préparer L-ergothionéine dans un véhicule acceptable sur le plan pharmaceutique afin d'obtenir un agent conçu pour être appliqué de façon localisée à l'épiderme ou, également, pour être administré par voie orale ou parentérale. On optimise l'application et l'administration efficaces de L-ergothionéine en l'encapsulant dans un liposome, selon un mode de réalisation préféré. L'invention concerne également des procédés diagnostiques servant à déterminer l'exposition et la susceptibilité au rayonnement, aux radicaux et à l'oxygène réactif chez les mammifères.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3874997P | 1997-02-20 | 1997-02-20 | |
| US60/038,749 | 1997-02-20 | ||
| US26198198A | 1998-02-19 | 1998-02-19 | |
| US09/026,198 | 1998-02-19 | ||
| PCT/US1998/003352 WO1998036748A1 (fr) | 1997-02-20 | 1998-02-20 | Procedes et compositions servant a proteger les mitochondries |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2281799A1 true CA2281799A1 (fr) | 1998-08-27 |
Family
ID=31719992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002281799A Abandoned CA2281799A1 (fr) | 1997-02-20 | 1998-02-20 | Procedes et compositions servant a proteger les mitochondries |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2281799A1 (fr) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2992882A1 (fr) * | 2014-09-05 | 2016-03-09 | China Medical University | Utilisation d'ergothionéine pour induire l'activité de nrf2 dans une cellule |
| CN111033261A (zh) * | 2017-06-27 | 2020-04-17 | 科里奥利医药研究有限责任公司 | 聚山梨醇酯的定量分析 |
| CN116390722A (zh) * | 2022-01-28 | 2023-07-04 | 南京纽邦生物科技有限公司 | 预防或改善皮肤老化的方法和组合物 |
| CN116459246A (zh) * | 2022-12-28 | 2023-07-21 | 华熙生物科技股份有限公司 | 麦角硫因在制备预防或抑制由乙醛引起的细胞损伤产品中的应用 |
| WO2023143184A1 (fr) * | 2022-01-28 | 2023-08-03 | Nanjing Nutrabuilding Bio-Tech Co., Ltd. | Compositions et procédés de prévention ou d'amélioration du vieillissement prématuré de la peau |
| CN118576592A (zh) * | 2023-03-02 | 2024-09-03 | 中国科学院高能物理研究所 | 麦角硫因或其组合物在制备辐射防护剂中的应用 |
-
1998
- 1998-02-20 CA CA002281799A patent/CA2281799A1/fr not_active Abandoned
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2992882A1 (fr) * | 2014-09-05 | 2016-03-09 | China Medical University | Utilisation d'ergothionéine pour induire l'activité de nrf2 dans une cellule |
| CN111033261A (zh) * | 2017-06-27 | 2020-04-17 | 科里奥利医药研究有限责任公司 | 聚山梨醇酯的定量分析 |
| CN116390722A (zh) * | 2022-01-28 | 2023-07-04 | 南京纽邦生物科技有限公司 | 预防或改善皮肤老化的方法和组合物 |
| WO2023143184A1 (fr) * | 2022-01-28 | 2023-08-03 | Nanjing Nutrabuilding Bio-Tech Co., Ltd. | Compositions et procédés de prévention ou d'amélioration du vieillissement prématuré de la peau |
| CN116459246A (zh) * | 2022-12-28 | 2023-07-21 | 华熙生物科技股份有限公司 | 麦角硫因在制备预防或抑制由乙醛引起的细胞损伤产品中的应用 |
| CN118576592A (zh) * | 2023-03-02 | 2024-09-03 | 中国科学院高能物理研究所 | 麦角硫因或其组合物在制备辐射防护剂中的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6103746A (en) | Methods and compositions for the protection of mitochondria | |
| Gabizon et al. | Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice | |
| US8461136B2 (en) | Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy | |
| US7045550B2 (en) | Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy | |
| US6479533B1 (en) | Methods and compositions for the protection of mitochondria | |
| US8029770B2 (en) | Caffeine salt complexes and methods for using the same in the prevention or treatment of cancer | |
| US6753325B2 (en) | Composition and method for prevention, reduction and treatment of radiation dermatitis | |
| EP3283056B1 (fr) | Nanostructures comprenant des conjugués porphyrine de cobalt-phospholipide et des étiquettes polyhistidine | |
| Celia et al. | Liposomal delivery improves the growth-inhibitory and apoptotic activity of low doses of gemcitabine in multiple myeloma cancer cells | |
| Epperly et al. | Effectiveness of analogs of the GS-nitroxide, JP4-039, as total body irradiation mitigators | |
| Carbone et al. | Nanoencapsulation strategies for the delivery of novel bifunctional antioxidant/σ1 selective ligands | |
| EP3087996A1 (fr) | Compositions et procédés d'utilisation de protection post-radiation | |
| Elbassiouny et al. | Photodynamic diagnosis of parathyroid glands with nano-stealth aminolevulinic acid liposomes | |
| AU750909B2 (en) | Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage | |
| CA2281799A1 (fr) | Procedes et compositions servant a proteger les mitochondries | |
| US20130005824A1 (en) | Treatment of ischemic tissue | |
| Siminiak et al. | The effect of selected antiarrhythmic drugs on neutrophil free oxygen radicals production measured by chemiluminescence | |
| MXPA99007701A (en) | Methods and compositions for the protection of mitochondria | |
| KR100514009B1 (ko) | 1,2,4-벤조트리아진옥사이드제제 | |
| US10918599B2 (en) | Serum-stable compositions and methods for light-triggered release of materials | |
| WO2002098399A2 (fr) | Technique et compositions de traitement du cancer | |
| Veena et al. | Antitumor Effects of Palladium− α− Lipoic Acid Complex Formulation as an Adjunct in Radiotherapy | |
| CN112672735A (zh) | 对由辐射暴露引起的损伤的治疗和预防 | |
| WO2001070220A1 (fr) | Procede d'administration de taxane liposomal encapsule | |
| Srinivasan et al. | Delayed Type Hypersensitivity, and Postirradiation Survival of |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |